Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A therapeutic or prophylactic agent for corneal epithelial lesions and/or conjunctival epithelial lesions

A purpose, recovery agent technology, applied in the field of therapeutic or preventive agents for corneal epithelial lesions and/or conjunctival epithelial lesions, can solve the problems of easy damage, dry eyes, difficulty in using contact lenses, etc., and achieves a long consumption history. Effect

Active Publication Date: 2016-08-03
NIPPON SUISAN KAISHA LTD +2
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Dry eye disease is a condition in which lesions develop on the surface of the eye due to decreased or altered tear production, so that the eye becomes dry and prone to injury due to decreased tear volume and makes contact lens use difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A therapeutic or prophylactic agent for corneal epithelial lesions and/or conjunctival epithelial lesions
  • A therapeutic or prophylactic agent for corneal epithelial lesions and/or conjunctival epithelial lesions
  • A therapeutic or prophylactic agent for corneal epithelial lesions and/or conjunctival epithelial lesions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] production of n-3 fatty acids deficient animals

[0057] Feeds for experimental animals generally contain n-3 fatty acids with an appropriate DHA content; therefore, in order to generate n-3 fatty acid deficient animals, special feeds that do not contain n-3 fatty acids must be used. In addition, normally raised animals receive sufficient DHA intake from the placenta and mother's milk from before birth to weaning, so it is not easy to produce target n-3 fatty acid deficient animals within only one generation. With these facts in mind, an n-3 fatty acid deficient diet containing 7% fats and oils was prepared using AIN93G (the standard refined diet composition for mouse and rat nutrition studies published by the American Institute of Nutrition) as the basal diet. Feed (n-3Def, linolenic acid: 14.4%; alpha-linolenic acid: 0.1%). N-3 fatty acids (n-3Adq, linolenic acid: 14.3%; α-linolenic acid: 2.6%) containing α-linolenic acid (18:3, n-3) were used as normal feed. Fema...

Embodiment 2

[0079] Using the same fish oil as in Example 1 (refined fish oil EPA-28 (containing more than 28% EPA and more than 12% DHA) produced by Nippon Suisan Co., Ltd.), the effect on human corneal epithelial lesions was confirmed.

[0080] Protocol Summary

[0081] A double-blind trial was used to evaluate the efficacy of EPA and DHA on 27 subjects who were diagnosed with dry eye disease according to the diagnostic criteria for dry eye disease (2006, Dry Eye Society). Take active or placebo supplements for 12 weeks while continuing normal dry eye treatment with eye drops etc. The active group administered refined fish oil capsules (15 capsules) for a daily intake of 1,245 mg of EPA and 540 mg of DHA. The placebo group was administered medium-chain triglyceride (MCT) capsules (15 capsules). Efficacy was determined at a total of 5 times: before administration; weeks 4, 8 and 12 after administration; and week 4 of the follow-up period after administration.

[0082] Evaluate the fo...

Embodiment 3

[0094] Taking patients with symptoms of eye fatigue as objects, a double-blind randomized controlled trial was used to compare the effect between the active group and the placebo group, wherein the active group took 162mg of EPA, 784mg of DHA, and 59mg of anthocyanidin in the form of capsules daily and 17 mg of lutein, and the placebo group took capsules containing medium-chain triglycerides.

[0095] result

[0096] The number of subjects was 11 in the active group and 9 in the placebo group. Subjective symptom assessment was performed 4 weeks after the start of administration, at which time there was a statistically significant improvement in dryness in eye symptoms in the active group compared to the placebo group. In addition, in the active group, significant improvements were observed in eye symptoms in terms of fatigue, blinking, eye hyperemia, and blurred vision 4 weeks after the start of administration compared with before administration.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides effective and safe preventive and therapeutic drugs or supplements for corneal epithelial lesions and / or conjunctival epithelial lesions. Specifically, the present invention provides a therapeutic or preventive agent for corneal epithelial lesions and / or conjunctival epithelial lesions, characterized by comprising the following substances as active ingredients: eicosapentaenoic acid and / or behenic acid Carbasahexaenoic acid, glyceride or phospholipid containing said fatty acid as a constituent fatty acid, or lower alcohol ester of said fatty acid. Preferably, the therapeutic or prophylactic agent comprises EPA and / or DHA in the form of refined fish oil or refined krill oil. Corneal epithelial lesions and / or conjunctival epithelial lesions can be alleviated, or tears can be restored, when the therapeutic agent or preventive agent is ingested in a daily dose of about 50 mg to 5,000 mg based on the total amount of EPA and / or DHA or esters thereof quantity.

Description

technical field [0001] The present invention relates to the treatment and prophylaxis of eye diseases such as corneal epithelial lesions and / or conjunctival epithelial lesions caused by: dry eye, contact lenses and inner eyelashes Produced irritation, conjunctival calculus, viral conjunctivitis and allergic conjunctivitis. Background technique [0002] With the popularization of personal computers, mobile phones, etc., the number of people suffering from eye fatigue or feeling some kind of discomfort in the eyes is increasing. In particular, among contact lens users, complaints of discomfort from staring at screens, such as dry eyes and gritty sensations, are increasing. Eye dryness (ie, dry eye disease) has attracted attention as a cause of the symptoms. [0003] Dry eye disease is a condition in which lesions develop on the surface of the eye due to decreased or altered tear volume, thus making the eye dry and easily damaged due to decreased tear volume, and making conta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/202A61K31/232A61K31/355A61K31/661A61K35/60A61P27/02A61P43/00
CPCA61K31/202A61K31/232A61K31/355A61K31/661A61K35/60A61K35/612A61K2300/00A61K31/20A61P27/02A61P27/04A61P27/14A61P43/00A61K9/0053
Inventor 原马明子川端二功守口徹川北哲也坪田一男
Owner NIPPON SUISAN KAISHA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com